Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr

In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis

Sun Pharma gets FDA approval for new device to treat skin disease

Remedium Lifecare secures Rs. 182.7 crore export deal

The CDMO upgrade represents a transformational step for Remedium Lifecare

Biocon Q4 FY25 consolidated PAT jumps 153% to Rs. 344 Cr

For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.

Sai Life Sciences FY25 PAT higher by 105% to Rs. 170 Cr

PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%

Kwality Pharmaceuticals concludes regulatory audit for Zimbabwe

This marks yet another milestone in our series of successful audits over the past year

Indian School of Public Policy and Indegene announce strategic collaboration

ISPP will analyze health systems across states, identifying scalable models and actionable insights to strengthen India's healthcare delivery

Zydus receives final approval from USFDA for Glatiramer Acetate Injection

Glatiramer Acetate is the generic version of Copaxone 20 mg/ml, 40 mg/ml, Single-Dose Prefilled Syringes

Agilent inaugurates India Solution Center to accelerate innovation

Integrated facility to deliver end-to-end, customized workflows across life sciences, diagnostics, and applied markets

Granules India bags EcoVadis’ Gold Rating

The company's first-ever corporate-level submission to EcoVadis builds on years of operational and environmental excellence